HCA Healthcare (NYSE:HCA) PT Raised to $375.00

HCA Healthcare (NYSE:HCA) had its price target increased by investment analysts at Deutsche Bank Aktiengesellschaft from $359.00 to $375.00 in a research report issued on Friday, Benzinga reports. The firm presently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s target price suggests a potential upside of 16.72% from the stock’s previous close.

HCA has been the subject of several other research reports. StockNews.com cut HCA Healthcare from a “strong-buy” rating to a “buy” rating in a report on Sunday, June 16th. TD Cowen reduced their price target on HCA Healthcare from $371.00 to $360.00 and set a “buy” rating for the company in a report on Tuesday, April 30th. Oppenheimer upped their price target on HCA Healthcare from $330.00 to $345.00 and gave the stock an “outperform” rating in a report on Monday, April 29th. Barclays upped their price target on HCA Healthcare from $356.00 to $367.00 and gave the stock an “overweight” rating in a report on Monday, April 29th. Finally, Robert W. Baird initiated coverage on HCA Healthcare in a research note on Thursday, May 30th. They set an “outperform” rating and a $396.00 price objective for the company. Four research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $326.53.

HCA Healthcare Stock Down 6.4 %

HCA Healthcare stock opened at $321.28 on Friday. The company has a debt-to-equity ratio of 29.26, a quick ratio of 1.02 and a current ratio of 1.16. The business’s 50-day simple moving average is $325.96 and its two-hundred day simple moving average is $317.82. The company has a market cap of $84.15 billion, a PE ratio of 16.02, a PEG ratio of 1.59 and a beta of 1.69. HCA Healthcare has a fifty-two week low of $215.96 and a fifty-two week high of $344.20.

HCA Healthcare (NYSE:HCA) last issued its quarterly earnings data on Friday, April 26th. The company reported $5.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.01 by $0.35. The business had revenue of $17.34 billion during the quarter, compared to analysts’ expectations of $16.81 billion. HCA Healthcare had a return on equity of 674.49% and a net margin of 8.20%. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $4.93 EPS. Equities analysts anticipate that HCA Healthcare will post 20.92 EPS for the current year.

Insider Buying and Selling

In related news, EVP Michael S. Cuffe sold 1,600 shares of the stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $309.00, for a total value of $494,400.00. Following the completion of the transaction, the executive vice president now directly owns 34,124 shares in the company, valued at $10,544,316. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Michael S. Cuffe sold 6,311 shares of the stock in a transaction on Thursday, May 9th. The stock was sold at an average price of $316.88, for a total value of $1,999,829.68. Following the sale, the executive vice president now directly owns 29,624 shares in the company, valued at $9,387,253.12. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Michael S. Cuffe sold 1,600 shares of the firm’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $309.00, for a total value of $494,400.00. Following the completion of the sale, the executive vice president now owns 34,124 shares in the company, valued at $10,544,316. The disclosure for this sale can be found here. Over the last three months, insiders sold 12,397 shares of company stock worth $3,921,929. Company insiders own 1.60% of the company’s stock.

Institutional Trading of HCA Healthcare

Hedge funds and other institutional investors have recently bought and sold shares of the business. IMS Capital Management purchased a new position in shares of HCA Healthcare during the first quarter worth about $207,000. Railway Pension Investments Ltd grew its holdings in shares of HCA Healthcare by 3.6% during the first quarter. Railway Pension Investments Ltd now owns 148,367 shares of the company’s stock worth $49,485,000 after buying an additional 5,100 shares during the last quarter. DekaBank Deutsche Girozentrale grew its holdings in shares of HCA Healthcare by 45.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 96,506 shares of the company’s stock worth $31,920,000 after buying an additional 30,139 shares during the last quarter. Cetera Advisors LLC lifted its position in HCA Healthcare by 37.3% in the first quarter. Cetera Advisors LLC now owns 7,049 shares of the company’s stock valued at $2,351,000 after purchasing an additional 1,916 shares during the period. Finally, Cetera Investment Advisers lifted its position in HCA Healthcare by 205.2% in the first quarter. Cetera Investment Advisers now owns 18,753 shares of the company’s stock valued at $6,255,000 after purchasing an additional 12,608 shares during the period. 62.73% of the stock is currently owned by institutional investors and hedge funds.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.